Cytomegalovirus (CMV) Vaccine Study

Cytomegalovirus (CMV) Trials in Columbus

Aventiv Research is currently participating in an investigational Cytomegalovirus (CMV) vaccine study at our Columbus, Ohio location. Once infected with CMV, your body retains the virus for life. Most people don’t know they have CMV because it rarely causes problems in healthy people, but if you’re pregnant or if your immune system is weakened, CMV is cause for concern. Women who develop an active CMV infection during pregnancy can pass the virus to their babies, who might then experience symptoms.

Enroll Now

Cytomegalovirus (CMV) Vaccine Study

The primary objective of this clinical trial is to evaluate the safety, tolerability, immunogenicity, and efficacy of an investigational vaccine candidate compared to placebo to prevent primary CMV infection in participants.

We are specifically looking for volunteers who are:

  • Healthy females who are 18 – 40 years of age

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.

Type 2 Diabetes with Chronic Kidney Disease Study

Type 2 Diabetes with Chronic Kidney Disease Trials in Phoenix

Aventiv Research is currently participating in a chronic kidney disease study at our Phoenix, AZ location. Diabetic nephropathy is the kidney disease that occurs as a result of diabetes and is a serious kidney-related complication of type 1 diabetes and type 2 diabetes. It is also called diabetic kidney disease. About 25% of people with diabetes eventually develop kidney disease. Diabetic nephropathy affects your kidneys’ ability to do their usual work of removing waste products and extra fluid from your body. Advances in drug therapy are key to treating this disease at its early stages and preventing further damage.

Enroll Now

Type 2 Diabetes with Chronic Kidney Disease Clinical Trial

The objective of this study is to assess whether 1800 mg once daily Metformin DR compared to placebo improves HbA1c after 28 weeks of treatment in patients with T2DM with varying renal function. You maybe be eligible to participate in this study if you are:

  • At least 25 years old
  • Have a BMI 20.0 to 45.0 kg/m2
  • Have T2DM

Female Sexual Arousal Disorder Study

Female Sexual Arousal Disorder Trials at Aventiv Research Women’s Health

Aventiv Research is currently enrolling participants for a female sexual arousal disorder study at our Women’s Health location in Columbus, Ohio.

Enroll Now

Female Sexual Arousal Disorder Study

The primary objective of this study is to evaluate the efficacy of an investigational cream vs placebo cream in patients with FSAD. You may qualify for this study if:

  • You are a premenopausal woman, 21 years or older
  • You have been in a stable, monogamous, relationship that is secure and communicative, for at least 6 months
  • You have previously experienced ‘normal’ sexual functioning for at least 2 years or longer and are currently sexual active
  • You agree to continue using an acceptable form of birth control during the study
  • You have a body mass index (BMI) from 18 to 35 kg/m², inclusive
  • You are medically healthy with no clinically significant medical history

Oral Contraceptive Study

Contraceptive Trials at Aventiv Research Women’s Health

Aventiv Research is currently enrolling participants for an oral contraceptive study at our Women’s Health location in Columbus, Ohio.

Enroll Now

Oral Contraceptive Study

The primary objective of this study is to assess the efficacy of an investigational contraceptive therapy in healthy women 18 to 35 years of age who are at risk for pregnancy. You may qualify for this study if:

  • You are female between the ages of 18-35 years old
  • You are at risk of pregnancy (ie, having heterosexual vaginal intercourse at least once per month) and is seeking contraception
  • You have normal, regular menstrual cycles that are between 21 and 35 days in duration
  • You are in good physical and mental health, based on medical, surgical, and gynecological history

Primary Membranous Nephropathy Study

Primary Membranous Nephropathy Trials in Phoenix

Aventiv Research is currently participating in a primary membranous nephropathy study at our Phoenix, AZ location. Primary membranous nephropathy (pMN) is a kidney-specific, autoimmune disease. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Primary Membranous Nephropathy Clinical Trial

The primary objective of this study is to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of obinutuzumab as compared to tacrolimus, two FDA approved drugs, in patients with pMN. This is an open-label study, patients will get either obinutuzumab or tacrolimus. You maybe be eligible to participate in this study if you:

  • Are 18 to 75 years of age
  • Have a diagnosis of pMN according to renal biopsy prior to or during screening

Hyperkalemia Study

Hyperkalemia Trials in Phoenix

Aventiv Research is currently participating in a hyperkalemia study at our Phoenix, AZ location. Hyperkalemia is the medical term that describes a potassium level in your blood that’s higher than normal. Potassium helps your nerves and muscles, including your heart, work the right way. In the early stages of kidney disease, the kidneys can often make up for high potassium. But as kidney function gets worse, they may not be able to remove enough potassium from your body. Advanced kidney disease is a common cause of hyperkalemia. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Hyperkalemia Clinical Trial

The primary objective of this study is to evaluate the safety and pharmacodynamics of an investigational drug in different dose combinations to identify the best dose combination for further evaluation. The study will also assess the safety and efficacy of a 4-week treatment of the investigational drug at the optimal dose combination in patients with hyperkalemia. You maybe be eligible to participate in this study if you:

  • Are 18 to 85 years of age
  • Have chronic kidney disease
  • Have high potassium levels in your blood (hyperkalemia) between 5.1 to <6.5 mmol/L at screening

Polycystic Kidney Disease Study

Polycystic Kidney Disease Trials in Phoenix

Aventiv Research is currently participating in a polycystic kidney disease study at our Phoenix, AZ location. Polycystic kidney disease (PKD) is a genetic disorder that causes cysts to grow in the kidneys, where they can disrupt functioning. Health complications include high blood pressure and kidney failure. Most people with PKD will eventually need dialysis or a kidney transplant. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Polycystic Kidney Disease Clinical Trial

The objective of this study is to study the efficacy and safety of an investigational drug against placebo in adults with autosomal dominant polycystic kidney disease (ADPKD). You maybe be eligible to participate in this study if you:

  • Are 18 to 70 years of age
  • Have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD)

Hyperoxaluria Study

Hyperoxaluria Trials in Phoenix

Aventiv Research is currently participating in a hyperoxaluria study at our Phoenix, AZ location. Hyperoxaluria refers to a large amount of oxalate in the urine. Too much oxalate in the urine can lead to build-up of calcium oxalate crystals in the kidneys and urinary tract, which can lead to kidney stones, decreased kidney function, and even kidney failure. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Hyperoxaluria Clinical Trial

The objective of this study is to determine the efficacy and durability of an investigational drug against placebo in reducing urinary oxalate excretion in subjects with enteric hyperoxaluria. The study will also evaluate the long-term safety and treatment of the investigational drug against placebo on kidney stone disease progression and kidney function. You maybe be eligible to participate in this study if you:

  • Are at least 18 years of age
  • Have an underlying enteric disorder associated with malabsorption such as:
    • malabsorptive bariatric surgery a minimum of 12 months prior to screening
    • inflammatory bowel disease with small bowel involvement
    • short bowel syndrome
    • or other malabsorption syndrome with known or suspected history of history of calcium oxalate kidney stones or oxalate nephropathy
  • Have had at least one documented kidney stone within 2 years prior to screening

Note: people who have had restrictive-only bariatric procedures (i.e vertical banded gastroplasty, adjustable gastric banding, sleeve gastrectomy) are not eligible to participate in the study.

Obesity with Type 2 Diabetes

Obesity Trials in Dublin, Ohio

Aventiv Research is currently participating in a obesity study at our Dublin, Ohio location. Obesity affects more than one-third of adults in America and results from an energy imbalance where the amount of calories consumed are greater than the amount of calories expelled. This can be caused by genetics, eating habits, location, and well-being. Individuals who are obese are more likely to suffer from type 2 diabeteshypertension, certain types of cancer and more. In addition to being life-altering and potentially fatal, these conditions put individuals at an increased risk of developing cardiovascular disease.

Enroll Now

Obesity with Type 2 Diabetes Study

The primary objective of this study is to evaluate the efficacy and safety of an investigational drug compared to placebo on the maintenance of weight loss in study participants who have Type 2 Diabetes, and have obesity or are overweight. You may qualify for our obesity study if:

  • You are at least 18 years of age
  • Have type 2 diabetes
  • Have a history of at least one self-reported unsuccessful dietary effort to lose body weight
  • Have a BMI of ≥27 kg/m2

Ticagrelor Reversal Study

Ticagrelor Reversal Study in Columbus, OH

Aventiv Research in Columbus is currently enrolling healthy volunteers for a phase 1 clinical trial at our Columbus, Ohio location to study an investigational drug to reverse the effects of another drug called ticagrelor. Ticagrelor (also called Brilinta®) is an approved drug used to help reduce clotting of your blood. A reversal drug helps restore blood’s ability to form clots which is very important if there is life threatening bleeding or serious injury.

Enroll Now

Ticagrelor (Brilinta®) Reversal Study

The primary objective of this clinical trial is to demonstrate reversal of the antiplatelet effects of ticagrelor with an investigational intravenous drug vs. placebo. This research study will require you to visit Aventiv Research for five consecutive overnight stays as well as subsequent follow up visits.

Qualified participants must be:

  • In general good health and well-controlled existing medical conditions
  • Male or female between 50-80 years old
  • Willing to take daily Aspirin 81 mg

Patients potentially may not qualify if they:

  • They have had a significant acute illness, medical/surgical procedure, or trauma within 4 weeks of the administration of study drug
  • Have any planned surgical procedure within the next 2 months
  • Are unable to stay in-house during the specified periods